SCHEMBL14733931

SCHEMBL14733931

Cc1nn(-c2ccccc2)c(C)c1CCC(C)C

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.62
RAB9A P51151 2/20 0.62
MEN1 O00255 1/20 0.59
KMT2A Q03164 1/20 0.59
TSHR P16473 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.50
P2RX7 Q99572 6/20 0.47
KDM4E B2RXH2 2/20 0.45
POLB P06746 1/20 0.45
APEX1 P27695 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
MAPT P10636 3/20 0.44
ALDH1A1 P00352 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
MAPK1 P28482 1/20 0.44
THRB P10828 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
PDE4D Q08499 1/20 0.43
SMO Q99835 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23046929 0.84 MEN1 (0.62) NPC1RAB9AMEN1KMT2ATSHR
SCHEMBL12844535 0.82 NPC1 (0.68) NPC1RAB9AMEN1KMT2ATSHR
SCHEMBL19675733 0.81 NPC1 (0.66) NPC1RAB9AMEN1KMT2ATSHR
SCHEMBL20083710 0.81 NPC1 (0.66) NPC1RAB9AMEN1KMT2ATSHR
SCHEMBL12770960 0.78 MEN1 (0.68) NPC1RAB9AMEN1KMT2ATSHR
SCHEMBL14438321 0.77 MEN1 (0.70) NPC1RAB9AMEN1KMT2ATSHR
SCHEMBL11250227 0.77 MEN1 (0.66) NPC1RAB9AMEN1KMT2ATSHR
SCHEMBL12775779 0.74 MEN1 (0.62) NPC1RAB9AMEN1KMT2ATSHR
SCHEMBL14451978 0.74 MEN1 (1.00) NPC1RAB9AMEN1KMT2ATSHR
SCHEMBL2216798 0.74 MEN1 (0.65) NPC1RAB9AMEN1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748433-B2 β3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2014-06-10 US disclosed
US-20130053403-A1 NOVEL BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME LLC 2013-02-28 US disclosed
US-20130053403-A1 NOVEL BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME LLC 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053403-A1 NOVEL BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 NPC1 1398/4885RAB9A 2134/4885MEN1 4423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.